About Biocon Biocon's Products & Services Research & Development Biocon's Technology Investors Media Careers CSR
 
 

About Us
  Research & Development
  Biopharmaceuticals
  Branded Formulations
  Financial Results
  - Investor Call Invite
  - Investor Presentation
  - Disclosure to Stock Exchange
  - Annual Reports

 Annual Report 2019

Annual Report 2018

  Downloads
  - Biocon's Journey of Fortitude
  - Biocon Profile
  - CMD Profile
  - Video Gallery
 
 
 


 
 

  Biocon Academy

Email:
admissions@bioconacademy.com

  Facilities Virtual Tour
     
 

Biocon is Asia’s premier biopharmaceutical company that is driven by the vision to make a difference to global healthcare through improved access to high quality, life-saving biotherapeutics by making them affordable for patients across the world.

We have evolved from manufacturing pharmaceuticals like statins and immunosuppresants, to discovering, developing and producing biologics in chronic therapies such as diabetes, oncology and immunology for global markets. This has translated into a diversified and differentiated pipeline of fermentation-derived complex generics, biosimilars that include insulins and monoclonal antibodies, and novel biologics.

Biocon was among the early movers in industry to pursue a high risk strategy of developing biosimilars for global markets. Through our ‘Made in India’ biosimilars business, we seek to pursue a humanitarian path that will provide affordable access to high quality generic biologics to make a difference to diabetes, cancer and autoimmune diseases. We have succeeded in bringing the benefit of high quality biosimilars to patients in India, other emerging market countries in Latin America, Africa, Middle East & Turkey, Asia-Pacfic regions and also now in developed markets of U.S., EU and Japan.

A combination of specialized talent, state-of-the-art research and manufacturing infrastructure and a culture of deep science and regulatory compliance have differentiated us in the marketplace and given us a distinct competitive edge. It has also led to Biocon being recognized as a credible global biopharmaceuticals player.

read more...

 
   

Biocon Performance Highlights of Q1FY20 by Kiran Mazumdar-Shaw, CMD, Biocon Ltd.




Biocon Corporate Overview
Stock Update
 

 

Company Announcements

 
 

Sep 12, 2019 
Biocon Licenses Three Generic Formulation Products to China Medical System Holdings

Aug 22, 2019 
Biocon's Malaysia Insulin Glargine Manufacturing Facility Receives EU GMP Certification, Provides Fillip to its Capacity

Aug 01, 2019 
Mylan and Biocon Launch First Trastuzumab Biosimilar, Ogivri, in Australia

 
 
  Media Coverage  
 

Aug 22, 2019:
Ramp-up of biosimilar portfolio to boost Biocon

Jul 26, 2019:
Biocon’s net rises 86%, revenue 25%

Jul 25, 2019:
Biocon net profit grows 72%

Jun 18, 2019:
Biosimilars, research key drivers for Biocon

 
 
 


 
 
 

Biocon Malaysia


 
 

Contact

Contact

Contact

     
  Biocon

Businesses

Recommended sites Biocon on  
  Home
About Us

Investor Relations
Media Relations
Careers
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Biopharmaceuticals
Research Services
Active Discovery Program

ABLE
Karnataka Vision Group on BT
Syngene International
Biocon Academy

    Linked In   
       
  Report adverse event/side effects and product complaints    
       
  * Disclaimer            © 2018, Biocon. All Rights Reserved